SCHEMBL16684696

SCHEMBL16684696

CCOC(=O)c1cc2ccc(F)cc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.49
PFKFB3 Q16875 1/20 0.49
AKR1B1 P15121 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
MAOB P27338 4/20 0.48
HPGD P15428 2/20 0.47
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
GLA P06280 1/20 0.47
CA3 P07451 1/20 0.47
GAA P10253 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16684605 0.88 MAOB (0.51) AKR1B1ALDH1A1MAPTKDM4EMAOB
SCHEMBL2246104 0.85 MAPT (0.51) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL742193 0.84 MIF (0.68) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL28367859 0.84 CYP1A2 (0.50) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL20559147 0.83 MAOA (0.46) ALDH1A1MAPTKDM4EMAOBHPGD
SCHEMBL17221595 0.82 MAOB (0.65) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL3499531 0.82 TBK1 (0.50) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL6332284 0.82 AKR1B1 (0.74) AKR1B1ALDH1A1MAPTKDM4EMAOB
SCHEMBL9612784 0.82 MAOB (0.71) MIFPFKFB3AKR1B1ALDH1A1MAPT
SCHEMBL15714288 0.82 HDAC4 (0.49) MIFPFKFB3AKR1B1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2025-04-29 US disclosed
EP-3704111-B1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2024-10-09 EP disclosed
CN-111886234-B Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2023-12-15 CN disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed
US-20210387980-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF Université de Montréal (CA) 2021-12-16 US disclosed
CN-111886234-A Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2020-11-03 CN disclosed
EP-3704111-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF Université de Montréal (CA) 2020-09-09 EP disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 MIF 2286/4885PFKFB3 2666/4885AKR1B1 1891/4885
US-12286426-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, IDH1 MIF 2286/4885PFKFB3 2666/4885AKR1B1 1891/4885
US-20210387980-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, NUTF2 MIF 2317/4885PFKFB3 2855/4885AKR1B1 2522/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 MIF 2317/4885PFKFB3 2855/4885AKR1B1 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.